Ciro Celsa

🔬 Introducing PHENO-RAG: the first validated AI framework for #HCC treatment decision support, now online on @JHEP_Reports With @m_giuffre, we combined LLMs + clinical guidelines + real-world patient data to help clinicians navigate complexity of #HCC. sciencedirect.com/science/articl…

Happy to share the results of this great international effort with @DJPinato. DT-Real study now published on @JHEP_Reports @PROMISE_UNIPA @unipa_it @imperialcollege

Liver cancer care has evolved from limited options to therapies that help patients live longer. 🩺 In this video, @DJPinato explores how #immunotherapy and collaboration are changing outcomes, with hope and responsibility at the core. Watch & share! #LiverCancerAwarenessMonth.

Please have a look at our editorial published in #ASCODailyNews @A_DAlessioMD @CiroCelsa @StephenLChan1 #IakovBolnykh @ASCO @HUNIMED @HumanitasMilano From Sorafenib to Precision Medicine: The Future of Systemic Therapy in Hepatocellular Carcinoma dailynews.ascopubs.org/do/sorafenib-p…

A great honour to receive @myESMO Merit Award for our abstract on the use of large language models in #HCC at #ESMOAI25 in collaboration with @m_giuffre @unipa_it @PROMISE_UNIPA

#ESMO25 💥 Great presentation of #mRNA4359 and Pembrolizumab 🗣️ @DJPinato 👥 Melanoma r/R PD-1/PD-L1 ✔️ ORR 24% ⬆️ ORR 64% if PDL1 >1% ✅ Translational data ☣️ 10% =>G3 @OncoAlert @myESMO @_SEOM @ASCO

@GraziaPennisi @SalvatorePetta @AlessandroMantovani @AleksanderKrag @marurinella @GiovanniTargher @PROMISE_UNIPA @unipa_it

Are hepatic and extrahepatic outcomes different in MetALD vs MASLD? Our meta-analysis now online on @LancetGastroHep shows MetALD associated with ⬆️ risk of ✓ Liver-related events ✓ #HCC ✓ Extrahepatic cancers Tailored approaches for #MetALD are needed thelancet.com/journals/langa…

Meta-analysis showed atezolizumab+bevacizumab most favorably balances OS and QoL for HCC. The combo reduces deterioration in global health, abdominal swelling, jaundice, pain vs sorafenib. @DJPinato ascopost.com/news/august-20… #HCC #Immunotherapy

Atezolizumab plus bevacizumab optimally balances quality of life preservation and survival benefits for patients with unresectable or advanced hepatocellular carcinoma. ja.ma/45OR4ph

@PROMISE_UNIPA @ImperialSandC @unipa_it

Quality of life matters in #HCC! Read our last network meta-analysis now online on @JAMAOnc @DJPinato @cabibbo78 @A_DAlessioMD @FulgenziClaudia @BeStef33 @gfmanfredi @paslombardi jamanetwork.com/journals/jamao…

Deeply honored to receive the Emerging Talent in #Hepatology award with friends and colleagues @FedRavaioli @AlessioGerussi @FrancescaRatti3 in a stunning venue in Bologna. Special thanks to Prof. @FabioPiscaglia and Prof. Invernizzi for this recognition @PROMISE_UNIPA @unipa_it

Read the #GUTOnline paper by @CiroCelsa et al on "Glucagon-like peptide-1 receptor agonist use is associated with a lower risk of major adverse liver-related outcomes: a meta-analysis of observational cohort studies" via bit.ly/3F5lcC6 In a meta-analysis of 11 cohort studies, including more than 1 million of patients with type 2 diabetes, GLP-1 agonists significantly reduce the risk of major liver-related outcomes and hepatic decompensation events. @PROMISE_UNIPA @unipa_it #GLP1s #T2DM #LiverDisease

@salvatorepetta @gra_penni @cabibbo78 @DJPinato @giovannitargher @alessandromantovani @PROMISE_UNIPA @unipa_it @ImperialSandC

📣Now online our new study on #GLP1RA and liver outcomes!🔬 GLP-1 agonists reduce risk of major adverse liver outcomes in T2 diabetes pts. Meta-analysis of 1.4+ million pts shows ⬇️ risk of decompensation and potential reduction in HCC #LiverTwitter gut.bmj.com/content/early/…

🤔Need for dedicated non-invasive tests in pts with chronic cholestatic diseases?

In press on @AGA_CGH our multicenter study 🇮🇹 🇬🇧 on 293 pts with PBC 🔥 Non-invasive tests for portal hypertension perform poorly when cholestasis is severe. 👊RESIST criteria (PLT+albumin) outperform stiffness-based criteria @VincenzaCalvar1 @MCarbone_80 cghjournal.org/article/S1542-…